HeartBeam (BEAT) Q1 2026 results: commercial partnerships launched, $11.5M raised, net loss improves. FDA-cleared 3D ECG platform advances heart attack detection. Read more.
HeartBeam's progress matters because its 3D ECG technology could revolutionize how heart attacks and arrhythmias are detected outside hospitals, potentially saving lives by enabling earlier intervention. The company's commercial partnerships and funding signal a step toward making this technology widely accessible, which could reduce healthcare costs and improve outcomes for millions at risk of cardiac events.
